PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+9.39%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$96.9M
AUM Growth
+$5.71M
(+6.3%)
Cap. Flow
+$6.09M
Cap. Flow
% of AUM
6.29%
Top 10 Holdings %
Top 10 Hldgs %
34.71%
Holding
119
New
16
Increased
37
Reduced
27
Closed
8
Avg Time Held
2
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LeMaitre Vascular
LMAT
|
+$2.55M |
| 2 |
Abbott
ABT
|
+$2.4M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$1.24M |
| 4 |
CryoPort
CYRX
|
+$1.17M |
| 5 |
Deluxe
DLX
|
+$977K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
STJ
St Jude Medical
STJ
|
+$5.1M |
| 2 |
SVU
SUPERVALU Inc.
SVU
|
+$1.19M |
| 3 |
Surmodics
SRDX
|
+$926K |
| 4 |
NVIDIA
NVDA
|
+$723K |
| 5 |
DTLK
Datalink Corp
DTLK
|
+$563K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.27% |
| 2 | Technology | 13.49% |
| 3 | Industrials | 9.45% |
| 4 | Energy | 3.46% |
| 5 | Communication Services | 3.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Axogen
AXGN
$2.09B
| $6.19M | 6.38% |
592,167
-3,741
| -0.6% | -$38.2K |
2013 Q3
14 quarters
|
|
2
NeoGenomics
NEO
$2.17B
| $4.11M | 4.24% |
520,275
-9,900
| -2% | -$80.6K |
2013 Q2
15 quarters
|
|
|
CSII
3
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.85M | 3.97% |
136,050
+8,500
| +7% | +$226K |
2013 Q2
15 quarters
|
|
|
4
Abbott
ABT
$178B
| $3.71M | 3.83% |
83,546
+55,471
| +198% | +$2.4M |
2014 Q1
12 quarters
|
|
|
VYNT
5
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $3.43M | 3.54% |
5,579
-178
| -3% | -$63.3K |
2015 Q4
5 quarters
|
|
6
Rockwell Medical
RMTI
$31.6M
| $3.04M | 3.14% |
4,413
+388
| +10% | +$256K |
2013 Q2
15 quarters
|
|
|
7
LeMaitre Vascular
LMAT
$1.89B
| $2.68M | 2.76% |
+108,675
| New | +$2.55M |
2017 Q1
0 quarters
|
|
8
AtriCure
ATRC
$2.9B
| $2.63M | 2.71% |
137,217
+9,467
| +7% | +$166K |
2013 Q2
15 quarters
|
|
9
Idexx Laboratories
IDXX
$41.4B
| $2.17M | 2.23% |
14,000
| – | – |
2013 Q3
14 quarters
|
|
10
Pfizer
PFE
$167B
| $1.85M | 1.91% |
56,999
-211
| -0.4% | -$6.65K |
2013 Q2
15 quarters
|
|
11
Tactile Systems Technology
TCMD
$501M
| $1.84M | 1.9% |
96,961
| – | – |
2016 Q3
2 quarters
|
|
|
ATRS
12
DELISTED
Antares Pharma, Inc.
ATRS
| $1.71M | 1.76% |
602,000
-5,000
| -0.8% | -$12K |
2016 Q3
2 quarters
|
|
13
Eli Lilly
LLY
$1.08T
| $1.7M | 1.75% |
20,200
+500
| +3% | +$40K |
2013 Q2
15 quarters
|
|
14
Apyx Medical
APYX
$108M
| $1.68M | 1.74% |
630,318
-1,717
| -0.3% | -$5.7K |
2015 Q1
8 quarters
|
|
15
Integer Holdings
ITGR
$4.31B
| $1.55M | 1.6% |
38,550
+750
| +2% | +$26.2K |
2016 Q4
1 quarter
|
|
16
DELISTED
Cogentix Medical, Inc.
CGNT
| $1.5M | 1.55% |
835,321
-86,648
| -9% | -$171K |
2015 Q2
7 quarters
|
|
17
Microsoft
MSFT
$3.98T
| $1.5M | 1.55% |
22,810
| – | – |
2014 Q1
12 quarters
|
|
|
ZIXI
18
DELISTED
Zix Corporation
ZIXI
| $1.35M | 1.39% |
280,889
-100
| -0% | -$493 |
2013 Q2
15 quarters
|
|
19
AbbVie
ABBV
$502B
| $1.28M | 1.32% |
19,675
+2,150
| +12% | +$135K |
2014 Q3
10 quarters
|
|
20
AT&T
T
$157B
| $1.25M | 1.29% |
39,802
+2,516
| +7% | +$79.2K |
2015 Q3
6 quarters
|
|
21
Ooma
OOMA
$554M
| $1.2M | 1.23% |
120,100
+9,650
| +9% | +$93K |
2016 Q4
1 quarter
|
|
22
Altria Group
MO
$121B
| $1.19M | 1.23% |
16,650
+500
| +3% | +$36.2K |
2015 Q4
5 quarters
|
|
23
IRIDEX
IRIX
$14.6M
| $1.19M | 1.22% |
100,000
+3,500
| +4% | +$49.2K |
2015 Q2
7 quarters
|
|
24
CVS Health
CVS
$115B
| $1.18M | 1.21% |
14,983
+3,600
| +32% | +$287K |
2013 Q2
15 quarters
|
|
25
Aflac
AFL
$58.8B
| $1.14M | 1.18% |
31,600
+3,000
| +10% | +$106K |
2015 Q2
7 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Perkins Capital Management held 119 positions worth $96.9M, up 6.3% from $91.2M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management deployed $6.09M of net new capital in Q1 2017, opening 16 new positions and adding to 37 existing holdings. Its largest new stake was LeMaitre Vascular: 108,675 shares worth $2.68M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 62% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was NVIDIA, an estimated $723K trimmed.
- Perkins Capital Management's largest Q1 2017 buy was LeMaitre Vascular: 108,675 shares worth $2.68M.
- Perkins Capital Management added most to Abbott in Q1 2017, an estimated $2.4M increase.
- Perkins Capital Management's biggest Q1 2017 reduction was NVIDIA, cutting an estimated $723K.
- Perkins Capital Management fully exited St Jude Medical in Q1 2017, selling an estimated $5.1M.
- Perkins Capital Management's ten largest holdings make up 35% of its $96.9M portfolio in Q1 2017.
- Perkins Capital Management opened 16 new positions and closed 8 in Q1 2017.
- Perkins Capital Management's portfolio value rose 6.3% quarter-over-quarter to $96.9M.
Based on Perkins Capital Management's 13F filing for Q1 2017, filed 19 Apr 2017.